Table 3. Therapeutic value of vaccination of pCAGGS(S) in HBV-Tg mice.
| HBsAg (ng/ml) | Anti-HBs (mIU/ml) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before | 2 weeks | 4 weeks | 8 weeks | 12 weeks | 32 weeks | Before | 2 weeks | 4 weeks | 8 weeks | 12 weeks | 32 weeks | |
| (a) 100 µg/mouse | ||||||||||||
| Female HBV-Tg mice | ||||||||||||
| No.1 | 50 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 1·25 | < 1·2 | < 1·25 | < 1·25 | < 1·25 | < 1·25 |
| No.2 | 48 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 1·25 | < 1·25· | < 1·25 | 11 | 82 | 65 |
| No.3 | 52 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 1·25 | < 1·25 | < 1·25 | 17 | 69 | 56 |
| No.4 | 29 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | < 1·25 |
| No.5 | 57 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | ND | < 1·25 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | ND |
| Male HBV-Tg mice | ||||||||||||
| No.1 | 120 | < 0·3 | 76 | 45 | ND | < 0·3 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | ND | < 1·25 |
| No.2 | 210 | 68 | 45 | ND | < 0·3 | < 0·3 | < 1·25 | < 1·25 | < 1·25 | ND | < 1·25 | < 1·25 |
| No.3 | 208 | < 0·3 | 98 | 48 | ND | < 0·3 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | ND | < 1·25 |
| No.4 | 105 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | 5·0 | < 1·25 |
| No.5 | 154 | < 0·3 | 52 | 25 | < 0·3 | < 0·3 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | 7·0 | < 1·25 |
| (b) (50 µg/mouse): Female HBV-Tg mice | ||||||||||||
| No.1 | 56 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | < 1·25 |
| No.2 | 52 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | < 1·25 |
| No.3 | 54 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | < 1·25 |
| No.4 | 50 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 0·3 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | < 1·25 |
| No.5 | 56 | < 0·3 | 12 | 8 | 7 | ND | < 1·25 | < 1·25 | < 1·25 | < 1·25 | < 1·25 | ND |
At the age of 6–7 weeks, 15 HBV-Tg mice (female 10 and male 5) were injected with a single intramuscular injection of 100 µg of pCAGGS(S) (a) or 50 µg of pCAGGS(S) (b). Serum HBsAg and anti-HBs levels were evaluated before and at 2, 4, 8, 12 and 32 weeks after vaccination by chemiluminescence enzyme immunoassay method. The detection limits of HBsAg and anti-HBs by these methods were 0·3 ng/ml and 1·25 mIU/ml, respectively.ND, not determined.